ARTICLE SUMMARY:
From the Coridea Incubator, whose founders delivered the first renal denervation therapy for hypertension, comes a new heart failure treatment that uses one of the body’s fluid volume management systems to relieve left-sided heart pressure.
The founders of the medical device incubator Coridea LLC have a history of developing device solutions for intractable diseases of the cardiac, renal, and pulmonary systems by digging deep into the physiologic mechanisms that drive them. By poking around in the autonomic nervous system, they’ve come up with novel targets amenable to neuromodulation.
